Business Description
Monte Rosa Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US61225M1027
Description
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.91 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | -0.34 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.42 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -28.3 | |||||
3-Year EPS without NRI Growth Rate | -16.7 | |||||
3-Year FCF Growth Rate | -0.2 | |||||
Future 3-5Y EPS without NRI Growth Rate | 7.82 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 58.51 | |||||
9-Day RSI | 60.57 | |||||
14-Day RSI | 59.97 | |||||
6-1 Month Momentum % | -20.28 | |||||
12-1 Month Momentum % | -28.64 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.56 | |||||
Quick Ratio | 6.56 | |||||
Cash Ratio | 6.19 | |||||
Days Sales Outstanding | 570.41 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.6 | |||||
Shareholder Yield % | 0.28 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -2420.89 | |||||
Net Margin % | -2264.53 | |||||
FCF Margin % | -1176.56 | |||||
ROE % | -68.31 | |||||
ROA % | -45.12 | |||||
ROIC % | -154.64 | |||||
ROC (Joel Greenblatt) % | -220.39 | |||||
ROCE % | -54.74 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 66.79 | |||||
PB Ratio | 1.53 | |||||
Price-to-Tangible-Book | 1.73 | |||||
EV-to-EBIT | -0.91 | |||||
EV-to-Forward-EBIT | -0.87 | |||||
EV-to-EBITDA | -0.96 | |||||
EV-to-Forward-EBITDA | -0.89 | |||||
EV-to-Revenue | 21.96 | |||||
EV-to-Forward-Revenue | 8.43 | |||||
EV-to-FCF | -1.87 | |||||
Price-to-Net-Current-Asset-Value | 2.45 | |||||
Price-to-Net-Cash | 2.72 | |||||
Earnings Yield (Greenblatt) % | -109.89 | |||||
FCF Yield % | -19.68 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GLUE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Monte Rosa Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 5.759 | ||
EPS (TTM) ($) | -2.24 | ||
Beta | 1.34 | ||
Volatility % | 107 | ||
14-Day RSI | 59.97 | ||
14-Day ATR ($) | 0.577589 | ||
20-Day SMA ($) | 4.5745 | ||
12-1 Month Momentum % | -28.64 | ||
52-Week Range ($) | 2.44 - 8.84 | ||
Shares Outstanding (Mil) | 61.37 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Monte Rosa Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Monte Rosa Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Monte Rosa Therapeutics Inc Frequently Asked Questions
What is Monte Rosa Therapeutics Inc(GLUE)'s stock price today?
The current price of GLUE is $6.33. The 52 week high of GLUE is $8.84 and 52 week low is $2.44.
When is next earnings date of Monte Rosa Therapeutics Inc(GLUE)?
The next earnings date of Monte Rosa Therapeutics Inc(GLUE) is 2024-11-08 Est..
Does Monte Rosa Therapeutics Inc(GLUE) pay dividends? If so, how much?
Monte Rosa Therapeutics Inc(GLUE) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |